Prasugrel with Percutaneous Coronary Intervention for Treating Acute Coronary Syndromes (TA317)

Technology Appraisal Guidance No. 317

Source: National Institute for Health and Care Excellence

1. Guidance

This guidance replaces NICE Technology Appraisal Guidance 182 issued in October 2009.

1.1  Prasugrel 10 mg in combination with aspirin is recommended as an option within its marketing authorisation, that is, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina [UA], non-ST segment elevation myocardial infarction [NSTEMI] or ST segment elevation myocardial infarction [STEMI]) having primary or delayed percutaneous coronary intervention.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (Review of TA182)

Issue Date: July 2014

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Review patients soon after starting opioids, says updated chronic pain guidance

Review patients soon after starting opioids, says updated chronic pain guidance

Revised chronic pain guidance from the Scottish Intercollegiate...

Contraceptive shortages reported by manufacturers

Contraceptive shortages reported by manufacturers

Shortages of several contraceptives, including combined,...

Hormone Replacement Therapy (HRT)

Hormone Replacement Therapy (HRT)

Hormone doses and costs of HRT preparations.

Drug shortages - live tracker

Drug shortages - live tracker

Added: FemSeven Sequi and FemSeven Conti.